Xenon Pharmaceuticals Inc (XENE) Stock Price, Quote & News

Company Profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as majo...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 484 3300

Website: www.xenon-pharma.com

Address:

200-3650 Gilmore Way, Burnaby, Canada

Quantumup May. 12 at 5:14 PM

Stifel reiterated $RAPP Buy; $56, and said: We remain Buy rated on RAPP following their 1Q26 report, where notably, the RAP-219 ph2 results in bipolar mania are now expected in 4Q26 (1H27 previously). $PRAX BHVN MPLT VNDA ALKS JAZZ UCBJY $XENE Here's what else Stifel said in its note to investors: https://x.com/Quantumup1/status/2054248241332412799?s=20

0 · Reply

MooseG May. 12 at 11:10 AM

$XENE too much institutional ownership, constant around 95% new money coming is institutions buying from other institutions

0 · Reply

OfficialStocktwitsUser May. 12 at 3:44 AM

$XENE RSI: 47.09, MACD: 0.3211 Vol: 1.56, MA20: 56.79, MA50: 55.36 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

DonCorleone77 May. 10 at 3:33 PM

$XENE $PRAX Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo Wells Fargo analyst Benjamin Burnett raised the firm's price target on Xenon Pharmaceuticals (XENE) to $69 from $68 and keeps an Overweight rating on the shares. The firm sees a high probability of approval of azetukalner in focal onset seizures. However, Praxis Precision's Phase 3 vormatrigine POWER1 data creates some near term risk for Xenon, the analyst tells investors in a research note.

1 · Reply

MarketBeat May. 9 at 8:08 AM

Xenon Pharmaceuticals Q1 Earnings Call Highlights $XENE https://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-q1-earnings-call-hi

0 · Reply

StocktwitsEarnings May. 7 at 9:40 PM

$XENE Q1 '26 Earnings Results & Recap Xenon Pharmaceuticals Inc. expects its $1.34B in cash, cash equivalents, and marketable securities to fund operations for at least 12 months and anticipates submitting an azetukalner NDA to the FDA in Q3 2026.

0 · Reply

Quantumup May. 7 at 1:19 PM

Raymond reiterated $RAPP Strong Buy; $66, and provided its thoughts on the stock. $XENE $PRAX BHVN MPLT VNDA JAZZ ALKS UCBJY Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2052377029060726819?s=20

0 · Reply

BillionerOfKing May. 5 at 3:56 PM

$XENE Current Stock Price: $57.16 Contracts to trade: $57.5 XENE May 15 2026 Call Entry: $1.55 Exit: $2.29 ROI: 48% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

MadMaverick Apr. 29 at 4:42 PM

NEURO BIOTECH + AI DRUG DISCOVERY 👇 $GANX Been keeping an eye on Gain Therapeutics — they're using their Magellan AI platform to go after the root cause of Parkinson's, not just the symptoms. Their lead drug GT-02287 works by restoring a key enzyme (GCase) that breaks down in PD patients. What's standing out: 🔹 Phase 1b showed an 81% avg drop in a key PD biomarker — first time ever seen with a GCase drug 🔹 Patients still showing stable motor scores at 5 months of dosing 🔹 They doubled their cash to $20.8M — funded through end of 2026 🔹 FDA Phase 2 IND expected Q2 → U.S. trial kicking off Q3 2026 🔹 Next-gen compound GT-04686 already prepped for the next stage Their pipeline stretches into Alzheimer's, Gaucher's, and Oncology — and the AI platform keeps generating new candidates. Big catalysts coming in the back half of 2026. One to watch. Communicated Disclaimer - DYOR. https://chartingdaily.com/structural-health Other neuro biotechs moving: $DNLI $BIVI $XENE $ANVS

1 · Reply

red75 Apr. 25 at 1:18 PM

$XENE following this stock

0 · Reply

Market Cap	5.39B
Revenue (ttm)	7.50M
Net Income (ttm)	-345.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,612.13%
Debt to Equity Ratio	0.00

Volume	789,600
Avg Vol	1,513,302
Day's Range	N/A - N/A
Shares Out	96.67M
Stochastic %K	5%
Beta	0.65
Analysts	Strong Sell
Price Target	$80.22